Page last updated: 2024-12-07
adn 138
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ADN 138: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 127323 |
| CHEMBL ID | 143895 |
| SCHEMBL ID | 10367313 |
| MeSH ID | M0154184 |
Synonyms (13)
| Synonym |
|---|
| adn 138 |
| adn-138 |
| CHEMBL143895 |
| 99434-90-9 |
| 8'-chloro-2',3'-dihydrospiro(pyrrolidine-3,6'(5'h)-pyrrolo(1,2,3-de)(1,4)benzoxazine)-2,5,5'-trione |
| spiro(pyrrolidine-3,6'(5'h)-pyrrolo(1,2,3-de)(1,4)benzoxazine)-2,5,5'-trione, 8'-chloro-2',3'-dihydro- |
| 8'-chloro-2',3'-dihydrospiro[pyrrolidine-3,6'(5'h)-pyrrolo[1,2,3-de][1,4]benzoxazine]-2,5,5'-trione |
| WSLOHMLGIVSUPR-UHFFFAOYSA-N |
| SCHEMBL10367313 |
| 8-chloro-5'-hydroxy-2,3-dihydro-5h-spiro[1,4-oxazino[2,3,4-hi]indole-6,3'-pyrrole]-2',5(4'h)-dione |
| DTXSID00912710 |
| 6-chlorospiro[9-oxa-1-azatricyclo[6.3.1.04,12]dodeca-4(12),5,7-triene-3,3'-pyrrolidine]-2,2',5'-trione |
| AKOS040750148 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID181872 | In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in sciatic nerve at 10 mg/kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
| AID34355 | In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-7 M | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
| AID184345 | In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in lens at 10 mg/Kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
| AID184326 | In vivo galactitol inhibitory activity measured by its ability to inhibit galactitol accumulation in diaphragm at 10 mg/kg/day | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
| AID34354 | In vitro aldose reductase inhibitory activity measured by NADPH-dependent inhibition of glyceraldehyde reduction in a partially purified bovine lens preparation at 10E-6 M | 1992 | Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24 | Novel spirosuccinimides with incorporated isoindolone and benzisothiazole 1,1-dioxide moieties as aldose reductase inhibitors and antihyperglycemic agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 52.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (52.35) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||